Caris Life Sciences launched MI FOLFOXai, an artificial intelligence-based predictor of response to FOLFOX chemotherapy in metastatic colorectal cancer that demonstrated approximately 50% improvement in overall survival across two independent validation studies.
The AI-powered predictor is using Caris Molecular Intelligence tumor profiling results, and is intended to gauge a patient’s likelihood of benefit from FOLFOX as a first-line regimen in combination with bevacizumab.
MI FOLFOXai was validated using two independent data sets to compare the increased benefit arm to the decreased benefit arm. The first study was a blinded, prospective analysis from retrospectively tested samples from the randomized phase III TRIBE2 study. This study showed a median overall survival improvement of 6.9 months. The second study involved several hundred cases with real-world evidence that showed a median overall survival increase of 11.8 months.
MI FOLFOXai was developed using a subset of results from the company’s proprietary Caris Molecular Intelligence platform, which includes next generation sequencing for DNA mutations, copy number alterations, insertions/deletions; whole transcriptome sequencing for RNA fusions and variant transcripts; and protein testing via immunochemistry. Machine learning algorithms were then used to create a molecular signature that was validated using the two independent data sets to compare the increased benefit arm to the decreased benefit arm.
